AstraZeneca to Invest $1.5B in New Manufacturing Facility

The plant will manufacture antibody-drug conjugates.

Kristen Kazarian, Managing Editor

May 20, 2024

1 Min Read
AstraZeneca to build ADC manufacturing plant
The pharma giant has expanded in other countries recently as well.Love Employee/iStock/Getty Images Plus via Getty Images

AstraZeneca has plans to build a $1.5 billion manufacturing facility in Singapore to produce a promising category of cancer-killing drugs called antibody-drug conjugates.

The facility will be the pharmaceutical company's first end-to-end ADC production site and supported by the Singapore Economic Development Board, reports Reuters.

AstraZeneca has been expanding into markets including China, Indonesia, and India over the last few years in an effort to widen its supply chain. Its breast cancer therapy Enhertu is made by its partner Daiichi Sankyo in Japan.

“AstraZeneca has built an industry-leading portfolio of cancer medicines including antibody drug conjugates which have shown enormous potential to replace traditional chemotherapy for patients across many settings, said Pascal Soriot, CEO, AstraZeneca.

"Singapore is one of the world’s most attractive countries for investment given its reputation for excellence in complex manufacturing, and I am excited for AstraZeneca to locate our $1.5 billion ADC manufacturing facility in the country," he added.

ADCs are engineered antibodies that bind to tumor cells and then release cell-killing chemicals.

AstraZeneca has a wide portfolio of in-house ADCs, which includes six wholly owned ADCs in clinic and more in pre-clinical development.

Economic Development Board Chairman Png Cheong Boon welcomed AstraZeneca's plans, saying it supported Singapore's development and manufacturing of precision medicines, and helped create jobs and economic opportunities.

Construction will begin by the end of 2024 and it should be operational in 2029, the company said, adding it will have zero carbon emissions from its first day of operations.

About the Author(s)

Kristen Kazarian

Managing Editor

Kristen Kazarian has been a writer and editor for more than three decades. She has worked at several consumer magazines and B2B publications in the fields of food and beverage, packaging, processing, women's interest, local news, health and nutrition, fashion and beauty, automotive, and computers.

Sign up for the Powder & Bulk Solids Weekly newsletter.

You May Also Like